Résztvevőt keres itt: Franciaország2/3. fázis
CIRAANO: Multimodal exploration of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.
A legfontosabb adatok
- Ki végzi
- Institut National De La Sante Et De La Recherche Medicale
- Hol
- Caen (Franciaország)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 600 fő, tervezett
- Kezdés
- 2026. jún. 4.
- Várható befejezés
- 2036. márc. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. január 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat több csoportot keres: színészeket, memóriasportolókat, egészséges önkénteseket és különböző okú memóriazavarral élő embereket. Mindenki agyi képalkotó vizsgálaton és memóriateszteken vesz részt.
- Életkor
- A legtöbb csoportnál 18 éves vagy idősebb. A szubjektív kognitív hanyatlásnál, az Alzheimer-kór miatti enyhe kognitív zavarnál, az Alzheimer-demenciánál és a Lewy-testes demenciánál 60 éves vagy idősebb. A szemantikus demenciánál 50 éves vagy idősebb.
- Nem
- Minden nem részt vehet.
- A betegség stádiuma
- A csoportok: szubjektív kognitív hanyatlás, Alzheimer-kór miatti enyhe kognitív zavar, valószínű Alzheimer-kór miatti demencia, valószínű Lewy-testes demencia, szemantikus demencia, alkoholhasználati zavar, nem degeneratív amnézia és 1-es típusú narkolepszia.
- Korábbi kezelés
- Az alkoholhasználati zavarral élőknek méregtelenítésen kell átesniük, nem lehet elvonási tünetük, nem szedhetnek benzodiazepint, és tartózkodniuk kell a pszichoaktív szerektől. Az Alzheimer-kór elleni gyógyszerek adagjának 8 hétig stabilnak kell lennie.
- Biomarker vagy leletérték
- Az 1-es típusú narkolepszia esetén rövid elalvási idő kell az alvásteszten kataplexiával, vagy alacsony hipokretinszint az agy-gerincvelői folyadékban.
A részvétel fő kizáró okai
- Terhes vagy szoptató nők
- Nem végezhető el náluk az MRI vagy az Amyvid és Tauvid PET-vizsgálat
- Súlyos depresszió (az egészséges önkénteseknél, színészeknél és memóriasportolóknál közepes depresszió is kizáró)
- Skizofrénia, pszichotikus zavar vagy bipoláris zavar
- Korábbi agyi vagy idegrendszeri betegség, amely befolyásolhatja a memóriát vagy a képalkotást
A regiszter feltételei, szó szerint
Mind a 69 feltétel megnézéseKevesebb
Ki vehet részt
- [all participants] Minimum education level of 7 years (at least equivalent to the French Certificat d’Études Primaires (CEP))
- [HC] Aged 18 or older
- [HC] Neuropsychological performance within the normal range for age and education level on all inclusion battery tests (±1.65 standard deviation)
- [HC] Be considered capable of complying with the protocol according to the investigator's judgment
- [ATHL] Aged 18 or older
- [ATHL] Must have participated in a memory competition—international, European, or national level
- [ATHL] Be considered capable of complying with the protocol according to the investigator's judgment
- [SCD] Aged 60 or older
- [SCD] Recruited from memory clinics
- [SCD] Must meet recognized criteria for subjective cognitive decline in the context of the preclinical stage of Alzheimer’s disease
- [MCI-AD] Aged 60 or older
- [all participants] Native French speaker and educated in French
- [MCI-AD] Recruited from memory clinics
- [MCI-AD] Must meet current recognized clinical criteria for mild cognitive impairment due to Alzheimer’s disease
- [D-AD] Aged 60 years or older
- [D-AD] Recruited from memory clinics
- [D-AD] Meeting current and recognized clinical criteria for major neurocognitive disorder due to probable Alzheimer’s disease
- [LBD] Aged 60 years or older
- [LBD] Recruited from memory clinics
- [LBD] Meeting current and recognized clinical criteria for probable Lewy body dementia or probable prodromal Lewy body dementia (mild cognitive impairment with Lewy bodies)
- [svPPA] Aged 50 years or older
- [svPPA] Recruited from memory clinics
- [all participants] Affiliated with a French social security scheme or beneficiary of such a scheme
- [svPPA] Meeting current and recognized clinical criteria for semantic dementia
- [AUD] Aged 18 years or older
- [AUD] Recruited from an addiction treatment service
- [AUD] Undergoing treatment primarily for an alcohol use disorder at the time of inclusion
- [AUD] Detoxified, with withdrawal symptoms resolved (Cushman score <3, Cushman et al., 1985) and benzodiazepines discontinued at the time of inclusion
- [AUD] Abstinent from all psychoactive substances (except tobacco and prescribed medication) at the time of inclusion
- [AMN] Aged 18 years or older
- [AMN] Recruited from hospital services or residential facilities housing patients with non-degenerative amnesic syndromes
- [AMN] Presenting with major cognitive impairment : Characterized primarily by severe episodic memory deficits (anterograde amnesia), possibly associated with retrograde amnesia and/or other impairments ; Leading to significant impacts on daily functioning and reduced autonomy ; Persistent and stable over time
- [NARCO] Aged 18 years or older
- [all participants] Willingness to undergo several days of assessments
- [NARCO] - Diagnosed with type 1 narcolepsy according to the 3rd edition of the International Classification of Sleep Disorders (ICSD-3), which includes daytime sleepiness persisting for more than 3 months, and either : Presence of cataplexy, mean sleep latency <8 minutes on the Multiple Sleep Latency Test (MSLT), and at least two REM sleep onsets (on MSLT and/or overnight polysomnography) ; Or cerebrospinal fluid hypocretin level <110 pg/mL
- [Informant] Aged 18 years or older
- [Informant] Spending at least one day per week with a relative included in one of the patient groups
- [all participants] Adherence to lifestyle considerations
- [all participants] Signed informed consent to participate in the study
- [ACT] Aged 18 or older
- [ACT] Must have performed in at least one theatre play in the last three years
- [ACT] Must be or have been a professional actor, either freelance or permanent (e.g., in a theatre company or at the Comédie-Française) for at least 5 years
Ki nem vehet részt
- [MCI-AD] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit
- [D-AD, LBD & svPPA] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) and/or L-DOPA for LBD patients, at non-stabilized doses within 8 weeks prior to the inclusion visit
- [all participants except informants] Chronic use of medications that affect cognition and/or may interfere with cognitive or imaging assessments (including non-tricyclic antidepressants, anticonvulsants such as lamotrigine, pregabalin, levetiracetam ; atypical antipsychotics; short-/intermediate-acting benzodiazepines such as alprazolam, lorazepam, oxazepam, temazepam; and sedative antihistamines), if doses were not stabilized within the 6 weeks prior to inclusion (except for changes due to withdrawal treatment in AUD patients)
- [all participants except informants] Participation in a clinical study involving exposure to ionizing radiation within the year prior to inclusion
- [all participants except informants] Current use of long-acting benzodiazepines, typical antipsychotics, tricyclic antidepressants, or first-generation antihistamines at the time of inclusion (unless related to withdrawal treatment in AUD patients), with discontinuation of such medication less than 3 months prior to inclusion
- [ACT & ATHL] Use of Alzheimer’s disease medications (including but not limited to donepezil, rivastigmine, galantamine, and memantine) at non-stabilized doses within 8 weeks prior to the inclusion visit
- [D-AD, LBD & svPPA] Absence of a caregiver or informant (i.e., a trusted person or relative who will be present from inclusion through the assessments, for patients with major cognitive impairment)
- [AUD & AMN] Evidence suggesting a probable neurodegenerative disorder (e.g., impairment in instrumental cognitive functions)
- [all participants except informants] Known hypersensitivity to Amyvid® or Tauvid®
- [all participants except informants] History of neurological or neurosurgical conditions that could significantly affect cognitive function and/or neuroimaging (e.g., head trauma with loss of consciousness >30 minutes, stroke, multiple sclerosis, insulin coma)
- [all participants except informants] Schizophrenia, psychotic disorders, or bipolar disorders (according to DSM-5 criteria)
- [all participants except informants] Presence of untreated chronic or acute illnesses (respiratory, cardiovascular, gastrointestinal, renal, metabolic, hematologic, endocrine, or infectious)
- [all participants except informants] Pregnant or breastfeeding women
- [all participants except informants] Presence of contraindications to MRI (e.g., claustrophobia, ferromagnetic objects in the body) or to Amyvid® and Tauvid® PET scans
- [SCD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
- [MCI-AD] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
- [D-AD, LBD & svPPA] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
- [D-AD, LBD & svPPA] Inability to understand instructions
- [AUD & AMN] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
- [NARCO] Presence of depressive symptoms (MADRS score > 34, threshold for severe depression)
- [all participants except informants] Current participation in a clinical trial and/or other research involving human participants (RIPH) if it includes imaging examinations using radiotracers
- [all participants except informants] Having a score suggesting an alcohol dependence (>9) on the FACE questionnaire (except for AUD patients)
- [all participants except informants] Physical, behavioral, or geographical limitations preventing participation in the study
- [all participants except informants] Refusal to cooperate during assessments
- [HC] Current or recent (within the last 5 years) theater practice
- [HC] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)
- [ACT & ATHL] Presence of depressive symptoms (MADRS score > 19, threshold for moderate depression)
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
- Centre Hospitalier Universitaire de Caen NormandieCaen, FranciaországRésztvevőt keres
- Groupement d'Interet public CYCERONCaen, FranciaországRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
[Part 2] to evaluate, in different categories of patients with memory disorders of various origins, the preservation or alteration of memory-related brain networks, associated with different types of memory strategies identified in memory experts.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvid® and Tauvid®) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
- A regiszteradat frissítve
- 2026. január 23.